Progress in Medicinal Chemistry

Progress in Medicinal Chemistry

1st Edition - March 14, 2019

Write a review

  • Editors: David Witty, Brian Cox
  • eBook ISBN: 9780444642783
  • Hardcover ISBN: 9780444642776

Purchase options

Purchase options
DRM-free (PDF, EPub, Mobi)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Progress in Medicinal Chemistry, Volume 58, provides a review of eclectic developments in medicinal chemistry, with each chapter written by an international board of authors. Topics covered in this new release include Amyotrophic lateral sclerosis (ALS), Covalent-binding Drugs, Natural Product Drug Delivery – A Special Challenge?, and SMN2 gene splicing modifier, and more.

Key Features

  • Provides extended, timely reviews of topics in medicinal chemistry
  • Contains targets and technologies relevant to the discovery of tomorrow’s drugs
  • Presents analyses of successful drug discovery programs


Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes

Table of Contents

  • 1. Covalent binders in drug discovery
    Maria A. Argiriadi, Aleksandra Baranczak, Michael M. Friedman, Julia Gavrilyuk, Adrian D. Hobson, Jonathan J. Hulce, Sami Osman, Noel S. Wilson and Anil Vasudevan
    2. Amyotrophic lateral sclerosis
    Klara Valko and Lukasz Ciesla
    3. Rewriting the (tran)script: Application to spinal muscular atrophy
    Hasane Ratni, Lutz Mueller and Martin Ebeling
    4. Natural product drug delivery: A special challenge?
    Neil J. Press, Emilie Joly and Peter Ertl

Product details

  • No. of pages: 197
  • Language: English
  • Copyright: © Elsevier 2019
  • Published: March 14, 2019
  • Imprint: Elsevier
  • eBook ISBN: 9780444642783
  • Hardcover ISBN: 9780444642776

About the Serial Editors

David Witty

David Witty
Dr David Witty has more than 20 years experience in the pharmaceutical industry as a medicinal chemist and project leader working principally in areas of anti-infectives, metabolic diseases, cognition and pain, delivering clinical candidates for several conditions. He led IT Strategy within the Neurology division of GSK, developing and deploying the first Electronic Notebooks for drug discovery to sites in the UK and Singapore. He has contributed more than 90 scientific papers, reviews, patents and books on medicinal and synthetic chemistry.

In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.

David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.

Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.

Affiliations and Expertise

WITNET LTD, Cambridge, UK

Brian Cox

Professor Brian Cox is at University of Sussex, Brighton, UK

Affiliations and Expertise

Professor, University of Sussex, Brighton, UK

Ratings and Reviews

Write a review

There are currently no reviews for "Progress in Medicinal Chemistry"